In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs Greg Scott joined Foley's Eye on China webinar on life science innovation >>Foley webinar...
|
Simcere Books Very Strong 2007
publication date: Mar 4, 2008
Simcere Pharma reported solid Q4 and 2007 results, and the company significantly increased its guidance for 2008. Simcere manufactures branded generic drugs, the patented cancer statin drug, Endu, and a treatment for stroke, Bicun. In 2007, Simcere generated revenues of 1.39 billion RMB ($190.5 million), an increase of 46% over 2006. Net income came in at 301 million RMB ($41.3 million) for the year, a 75% jump from 2006. Simcere is now predicting it will generate revenues in a range from 2 billion RMB to 2.1 billion RMB in 2008, with profits between 390 million RMB and 400 million RMB. More details...
Stock Symbol: (NYSE: SCR)
|
Partner Events
BioPharm America™ 2010Boston, MA, USA September 15–17, 2010 CALAsia 2010San Diego, USA October 4-5, 2010 CHINA PRETRIALS 2010: Global Preclinical Development Summit Beijing, China October 17-19, 2010 CHINA TRIALS 2010 Beijing, China November 7-9, 2010 12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM) Beijing, China November 9-11, 2010
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|